Fournier's gangrene and sodium-glucose co-transporter 2(SGLT2) inhibitors: Our experience
نویسندگان
چکیده
منابع مشابه
Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملsafety of sodium-glucose co-transporter 2 inhibitors during ramadan fasting: evidence, perceptions and guidelines
sodium-glucose co-transporter 2 (sglt2) inhibitors are a new glucose-lowering therapy for t2dm with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. they have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. there is some concern about the safety of using sglt2 inhibitors in muslim type 2 diabete...
متن کاملFungal Fourniers Gangrene in an Immunocompromised Patient
Fournier's Gangrene is a rapidly progressive necrotizing fasciitis of the groin, perianal and perineal region that is often polymicrobial in nature, often averaging 3 species of bacteria per patient. The typical infection can be due to a host of microbes, including gram positive, gram negative and anaerobic species including. Many of the causative organisms are found in the normal microbial flo...
متن کاملSodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and Mortality in type 2 diabetes (EMPA-REG OUTCOMES) trial, demonstrated reduced cardiovascular outcomes in peo...
متن کاملSodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors: A Review Authors
Worldwide, the number of individuals with diabetes is projected to rise from 366 million in 2011 to 552 million by end of 2030. Despite therapeutic advances, the incidence and prevalence of diabetes continues to surge exacting a tremendous economic burden on countries. The major problem with diabetes is that just 50% of population is able to achieve target glycaemic control with available medic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Endocrinology and Metabolism
سال: 2019
ISSN: 2230-8210
DOI: 10.4103/ijem.ijem_614_18